跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Tisotumab
首页
药物
Tisotumab
Tisotumab
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
METHODS OF TREATING CANCER WITH A COMBINATION OF A PLATINUM-BASED AGENT AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
EP 3768325 A4
申请人: GENMAB AS
优先权: 2018
CN
EP
US
WO
5 件公开
METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
EP 3814379 A4
申请人: GENMAB AS
优先权: 2018
CN
EP
US
WO
5 件公开
US 20250066507 A1
申请人: GENMAB AS
优先权: 2024
US
METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-VEGF ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
EP 3873533 A1
申请人: GENMAB AS
优先权: 2018
CN
EP
US
WO
5 件公开
METHODS OF TREATING CANCER WITH ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES
EP 4518904 A1
申请人: GENMAB AS
优先权: 2022
EP
US
WO
3 件公开
药物
反馈
